GRCL - Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies | Benzinga
AstraZeneca (NASDAQ:AZN) has announced an acquisition of Gracell Biotechnologies (NASDAQ:GRCL) that is expected to be completed in Q1 of 2024.
Under the terms of the agreement, AstraZeneca has agreed to give Gracell Biotechnologies $1.20 billion in in exchange for GRCL stock. Currently, neither company has disclosed whether the payment will be in cash or in stock.
About The Companies Involved
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major ...